EnteroBiotix
Glasgow · 3 known investors
Find your way into EnteroBiotix
279 people in our graph share verified history with the EnteroBiotix team — schools, employers, funds. One of them is your warm intro.
Mike Moradiunlockedknows Melissa Strange · together at Saïd Business School, University of Oxford (overlapped)
×6knows the team · via Saïd Business School, University of Oxford
knows the team · via BioIndustry Association (BIA)
×4knows the team · via Oxford Brookes University
EnteroBiotix is a clinical-stage microbiome therapeutics company developing EBX-102-02, an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome and other gastrointestinal and liver diseases. It uses proprietary AMPLA drying technology and MHRA-licensed GMP manufacturing, with a pipeline spanning IBS, liver cirrhosis, and adjuvant treatment in blood cancer.</parameter> <parameter name="founders">[]
Founders & leadership
JR
James Roger McIlroyFounder
MS
Melissa StrangeinChief Financial OfficerShe brings 17 years of life science industry experience in biotech, digital health and medtech, with expertise in financial management, tax strategy, corporate transactions, and public and private market fundraising across discovery through commercial phases.
JB
James BarnesinChief Operating OfficerHe brings approximately 20 years of experience in drug development, strategic leadership, and business operations across mid-size pharma, biotech, and consulting roles.
Board
DC
FA
Felix Andy Awili OlaleBoard director
IB
Iain BairdBoard director
MB
Mark BamforthinBoard directorGeneral Partner, KAMRA I Investment Committee Member at Kineticos Life Sciences
EJ
Elmar Josef SchneeBoard director
DL
David LawrenceBoard director
Investors · 3
Also in the syndicate · 1
Thairm Biolead
Reported raises · per SEC filings
Form D private placements$28.5M disclosed across 6 rounds · 2022–2026
▶$5.3MraisedApr 2026 · 6 investors · BiotechnologyRule 506(b)
▶$5.3MraisedApr 2026 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Iain BairdDirector
- Strange MelissaExecutive Officer
- Elmar Josef SchneeDirector
- Mark BamforthDirector
- James Roger McIlroyExecutive Officer, Director
- Douglas Campbell ThomsonDirector
- Barnes JamesExecutive Officer
- Amount sold
- $5.3M
- First sale
- Mar 2026
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
▶$1.4MraisedJul 2025 · 2 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJul 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elmar Josef SchneeDirector
- Douglas Campbell ThomsonDirector
- Felix Andy Awili OlaleDirector
- Iain BairdDirector
- Melissa StrangeExecutive Officer
- Mark BamforthDirector
- James BarnesExecutive Officer
- David LawrenceDirector
- James Roger McIlroyExecutive Officer, Director
- Amount sold
- $1.4M
- Minimum investment
- $33.9K
- First sale
- Jul 2025
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
▶$1.3MraisedApr 2024 · 1 investors · BiotechnologyRule 506(b)
▶$1.3MraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Iain BairdDirector
- Mark BamforthDirector, Promoter
- David LawrenceDirector
- Christopher LeaExecutive Officer, Director
- Elmar SchneeDirector
- Douglas ThomsonDirector
- James McIlroyExecutive Officer, Director
- Amount sold
- $1.3M
- Minimum investment
- $1.3M
- First sale
- Mar 2024
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
▶$2.6MraisedFeb 2024 · 3 investors · BiotechnologyRule 506(b)
▶$2.6MraisedFeb 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elmar SchneeDirector
- Mark BamforthDirector, Promoter
- Christopher LeaExecutive Officer
- Iain BairdDirector
- David LawrenceDirector
- Douglas ThomsonDirector
- James McIlroyExecutive Officer, Director
- Amount sold
- $2.6M
- Minimum investment
- $31.8K
- First sale
- Jan 2024
- Incorporated
- Other, United Kingdom
- Federal exemptions
- 06b
▶$6.7MraisedAug 2023 · 3 investors · BiotechnologyRule 506(b)
▶$6.7MraisedAug 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark BamforthDirector, Promoter
- James McIlroyExecutive Officer, Director
- Elmar SchneeDirector
- Iain BairdDirector
- David LawrenceDirector
- Douglas ThomsonDirector
- Amount sold
- $6.7M
- Minimum investment
- $127.6K
- First sale
- Aug 2023
- Incorporated
- Limited Liability Company, United Kingdom
- Federal exemptions
- 06b
▶$11.2MraisedSep 2022 · 5 investors · BiotechnologyRule 506(b)
▶$11.2MraisedSep 2022 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Iain J. BairdDirector
- Douglas Campbell ThomsonDirector
- David Muir LawrenceDirector
- James Roger McIlroyExecutive Officer, Director, Promoter
- Mark R. BamforthDirector, Promoter
- Offering amount
- $13M
- Amount sold
- $11.2M
- Minimum investment
- $117K
- First sale
- Aug 2022
- Incorporated
- Limited Liability Company, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with EnteroBiotix for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does EnteroBiotix do?
- EnteroBiotix is a clinical-stage microbiome therapeutics company developing EBX-102-02, an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome and other gastrointestinal and liver diseases. It uses proprietary AMPLA drying technology and MHRA-licensed GMP manufacturing, with a pipeline spanning IBS, liver cirrhosis, and adjuvant treatment in blood cancer.</parameter> <parameter name="founders">[]
- Who founded EnteroBiotix?
- EnteroBiotix was founded by James Roger McIlroy.
- Who are EnteroBiotix's investors?
- EnteroBiotix's investors include Scottish National Investment Bank, Scottish Enterprise.
- How much funding has EnteroBiotix raised?
- EnteroBiotix has disclosed $28.5M raised across 6 rounds.
- Where is EnteroBiotix headquartered?
- EnteroBiotix is headquartered in Glasgow.